Log in

IDEXX Laboratories Stock Price, News & Analysis (NASDAQ:IDXX)

$282.83
+0.70 (+0.25 %)
(As of 10/20/2019 04:00 PM ET)
Today's Range
$280.48
Now: $282.83
$283.44
50-Day Range
$265.47
MA: $276.73
$290.68
52-Week Range
$176.11
Now: $282.83
$292.17
Volume229,935 shs
Average Volume347,676 shs
Market Capitalization$24.35 billion
P/E Ratio66.39
Dividend YieldN/A
Beta0.82
IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments. Read More…

Industry, Sector and Symbol

Industry Diagnostic substances
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:IDXX
CUSIP45168D10
Phone207-556-0300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.21 billion
Cash Flow$5.35 per share
Book Value($0.11) per share
Price / Book-2,571.18

Profitability

Net Income$377.03 million

Miscellaneous

Employees8,377
Market Cap$24.35 billion
Next Earnings Date10/31/2019 (Confirmed)
OptionableOptionable

Receive IDXX News and Ratings via Email

Sign-up to receive the latest news and ratings for IDXX and its competitors with MarketBeat's FREE daily newsletter.


IDEXX Laboratories (NASDAQ:IDXX) Frequently Asked Questions

What is IDEXX Laboratories' stock symbol?

IDEXX Laboratories trades on the NASDAQ under the ticker symbol "IDXX."

How were IDEXX Laboratories' earnings last quarter?

IDEXX Laboratories, Inc. (NASDAQ:IDXX) issued its earnings results on Thursday, August, 1st. The company reported $1.43 EPS for the quarter, topping analysts' consensus estimates of $1.37 by $0.06. The company had revenue of $620.10 million for the quarter, compared to analysts' expectations of $627.10 million. IDEXX Laboratories had a net margin of 17.78% and a return on equity of 765.45%. The firm's revenue was up 6.8% compared to the same quarter last year. During the same quarter last year, the company earned $1.23 EPS. View IDEXX Laboratories' Earnings History.

When is IDEXX Laboratories' next earnings date?

IDEXX Laboratories is scheduled to release their next quarterly earnings announcement on Thursday, October 31st 2019. View Earnings Estimates for IDEXX Laboratories.

What guidance has IDEXX Laboratories issued on next quarter's earnings?

IDEXX Laboratories issued an update on its FY19 earnings guidance on Thursday, August, 1st. The company provided earnings per share (EPS) guidance of $4.82-4.92 for the period, compared to the Thomson Reuters consensus estimate of $4.82. The company issued revenue guidance of $2, compared to the consensus revenue estimate of $2.41 billion.

What price target have analysts set for IDXX?

6 Wall Street analysts have issued 1-year target prices for IDEXX Laboratories' shares. Their predictions range from $276.00 to $300.00. On average, they expect IDEXX Laboratories' stock price to reach $287.67 in the next year. This suggests a possible upside of 1.7% from the stock's current price. View Analyst Price Targets for IDEXX Laboratories.

What is the consensus analysts' recommendation for IDEXX Laboratories?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IDEXX Laboratories in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for IDEXX Laboratories.

What are Wall Street analysts saying about IDEXX Laboratories stock?

Here are some recent quotes from research analysts about IDEXX Laboratories stock:
  • 1. Canaccord Genuity analysts commented, "We think IDXX is likely due for a new product launch around 2020 or so, but whether they announce it at the Analyst Day, or VMX remains to be seen. We reiterate our Buy on IDXX and raise our PT to $285, as we roll forward to our new 2021 estimates. Q2 beat on the bottom, delivered small miss on the top. Q2 Adj. EPS of $1.43 (+16% rep, +19% FXN) beat our $1.35/Street’s $1.37 and OM of 26.5% (+140bps Y/Y) beat our 25.4%E, as G&A came in $5M below us (disciplined expense management, low benefit costs and LPD cost controls). Q2 revs of $620M (+7% rep., +9% FXN) missed our $625M/Street’s $627M (see shortfall rationale below). GMs of 57.7% grew 50bps Y/Y and matched us (helped by 2-3% price increases, and mix benefits). Q2 rev. shortfall." (8/2/2019)
  • 2. According to Zacks Investment Research, "IDEXX exited the first quarter on a promising note with better-than-expected earnings and revenues. Solid growth in organic revenues and a raised 2019 EPS guidance are encouraging. IDEXX witnessed strong gains in CAG Diagnostics recurring revenue and global premium instrument installed base in the quarter. The companion animal market fundamentals remain solid with tremendous global runway for growth. The innovation-based, multi-modality global strategy, enabled by enhanced commercial capability, accelerated recurring CAG Diagnostics revenue growth. Over the past three months, IDEXX outperformed its industry. On the flip side, Henry Schein’s recent spin out animal health business raises concern. This wing has merged with IDEXX’ peer Vet First Choice posing the company tough competition. Also, moderating global reference lab revenue growth along with high dependence on third-party distributors are a few overhangs for IDEXX." (5/3/2019)

Has IDEXX Laboratories been receiving favorable news coverage?

Headlines about IDXX stock have been trending somewhat positive on Sunday, according to InfoTrie. InfoTrie ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. IDEXX Laboratories earned a news impact score of 0.8 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for IDEXX Laboratories.

Are investors shorting IDEXX Laboratories?

IDEXX Laboratories saw a decrease in short interest in the month of September. As of September 30th, there was short interest totalling 1,160,000 shares, a decrease of 10.8% from the August 30th total of 1,300,000 shares. Based on an average trading volume of 389,500 shares, the short-interest ratio is presently 3.0 days. Approximately 1.4% of the company's shares are short sold. View IDEXX Laboratories' Current Options Chain.

Who are some of IDEXX Laboratories' key competitors?

What other stocks do shareholders of IDEXX Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IDEXX Laboratories investors own include NVIDIA (NVDA), Netflix (NFLX), Paypal (PYPL), Adobe (ADBE), Micron Technology (MU), Alibaba Group (BABA), Mastercard (MA), Intuitive Surgical (ISRG), Intel (INTC) and Home Depot (HD).

Who are IDEXX Laboratories' key executives?

IDEXX Laboratories' management team includes the folowing people:
  • Mr. Jonathan W. Ayers, Chairman, CEO & Pres (Age 63)
  • Mr. Brian P. McKeon, CFO, Exec. VP & Treasurer (Age 57)
  • Ms. Jacqueline L. Studer, Corp. VP, Gen. Counsel & Corp. Sec. (Age 60)
  • Mr. Giovani Twigge, Chief HR Officer & Corp. VP (Age 55)
  • Mr. Jay Mazelsky, Exec. VP of Companion Animal Group (Age 58)

Who are IDEXX Laboratories' major shareholders?

IDEXX Laboratories' stock is owned by a variety of of institutional and retail investors. Top institutional investors include CIBC Private Wealth Group LLC (0.40%), Stephens Investment Management Group LLC (0.31%), Welch & Forbes LLC (0.21%), Envestnet Asset Management Inc. (0.10%), Robeco Institutional Asset Management B.V. (0.07%) and Nisa Investment Advisors LLC (0.07%). Company insiders that own IDEXX Laboratories stock include Brian P Mckeon, Bruce L Claflin, Daniel M Junius, Giovani Twigge, Jacqueline Studer, Jay Mazelsky, Jonathan W Ayers, Lawrence D Kingsley, M Anne Szostak, Michael Lane, Rebecca M Henderson, Sophie V Vandebroek and William T End. View Institutional Ownership Trends for IDEXX Laboratories.

Which major investors are selling IDEXX Laboratories stock?

IDXX stock was sold by a variety of institutional investors in the last quarter, including CIBC Private Wealth Group LLC, Stephens Investment Management Group LLC, Douglass Winthrop Advisors LLC, Bright Rock Capital Management LLC, Gateway Investment Advisers LLC, IMS Capital Management, CenturyLink Investment Management Co and Robeco Institutional Asset Management B.V.. Company insiders that have sold IDEXX Laboratories company stock in the last year include Brian P Mckeon, Giovani Twigge, Jacqueline Studer, Jay Mazelsky, Jonathan W Ayers, M Anne Szostak, Michael Lane, Rebecca M Henderson and Sophie V Vandebroek. View Insider Buying and Selling for IDEXX Laboratories.

Which major investors are buying IDEXX Laboratories stock?

IDXX stock was purchased by a variety of institutional investors in the last quarter, including Scout Investments Inc., Envestnet Asset Management Inc., State of Alaska Department of Revenue, Decatur Capital Management Inc., Tuttle Tactical Management, Commerzbank Aktiengesellschaft FI, Baldwin Brothers Inc. MA and First Citizens Bank & Trust Co.. Company insiders that have bought IDEXX Laboratories stock in the last two years include Bruce L Claflin and Lawrence D Kingsley. View Insider Buying and Selling for IDEXX Laboratories.

How do I buy shares of IDEXX Laboratories?

Shares of IDXX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is IDEXX Laboratories' stock price today?

One share of IDXX stock can currently be purchased for approximately $282.83.

How big of a company is IDEXX Laboratories?

IDEXX Laboratories has a market capitalization of $24.35 billion and generates $2.21 billion in revenue each year. The company earns $377.03 million in net income (profit) each year or $4.26 on an earnings per share basis. IDEXX Laboratories employs 8,377 workers across the globe.View Additional Information About IDEXX Laboratories.

What is IDEXX Laboratories' official website?

The official website for IDEXX Laboratories is http://www.idexx.com/.

How can I contact IDEXX Laboratories?

IDEXX Laboratories' mailing address is ONE IDEXX DRIVE, WESTBROOK ME, 04092. The company can be reached via phone at 207-556-0300 or via email at [email protected]


MarketBeat Community Rating for IDEXX Laboratories (NASDAQ IDXX)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  440 (Vote Outperform)
Underperform Votes:  292 (Vote Underperform)
Total Votes:  732
MarketBeat's community ratings are surveys of what our community members think about IDEXX Laboratories and other stocks. Vote "Outperform" if you believe IDXX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IDXX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/20/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel